New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
19:09 EDTDRTX, MDR, MDCO, AMRN, VRNT, ARTX, CBSTOn The Fly: After Hours Movers
HIGHER: Durata Therapeutics (DRTX), up 5.4% after an FDA Committee voted in favor of its Dalvance injection for the treatment of adult patients with acute bacterial skin and skin structure infections caused by certain bacteria... Amarin (AMRN), up 8.8% after announcing a co-promotion agreement with Kowa Pharmaceuticals America for its Vascepa capsules in the U.S... Verint Systems (VRNT), up 10% after reporting earnings that beat expectations and providing a fiscal year outlook that also topped estimates. LOWER: The Medicines Company (MDCO), down 14.3% after Durata and Cubist Pharmaceuticals (CBST) each received positive votes from FDA panels for bacteria treatments that could compete with its Oritavancin. Cubist (CBST), which confirmed the FDA panel vote intraday, saw shares gain $3.05, or 4.35%, to close at $73.15 for the session... Arotech (ARTX), down 12.5% after reporting fiscal year earnings and revenue that disappointed... McDermott (MDR), down 2.8% after filing to sell 10M tangible equity units and, in a separate release, saying that its first quarter results may differ "substantially" from the company's current expectation.
News For DRTX;MDR;MDCO;AMRN;VRNT;ARTX;CBST From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 22, 2014
07:11 EDTMDCOMedicines Co. says Angiomax, Angiox revenue up 5% in first nine months
Subscribe for More Information
07:06 EDTMDCOThe Medicines Co. reports Q3 EPS (26c) , consensus (12c)
Subscribe for More Information
October 21, 2014
17:13 EDTCBSTCubist sees FY14 revenue $1.19M-$1.28M, consensus $1.2B
Subscribe for More Information
16:01 EDTCBSTCubist reports Q3 EPS 58c, may not compare to consensus 4c
Subscribe for More Information
15:30 EDTCBSTNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Yahoo! (YHOO), consensus 30c; ACE (ACE), consensus $2.34; Discover Financial (DFS), consensus $1.34; Pinnacle Financial (PNFP), consensus 51c; Broadcom (BRCM), consensus 84c; Intuitive Surgical (ISRG), consensus $3.80; FMC Technologies (FTI), consensus 74c; Robert Half International (RHI), consensus 58c; E-Trade (ETFC), consensus 22c; Nabors Industries (NBR), consensus 36c; Waste Connections (WCN), consensus 54c; Cubist Pharmaceuticals (CBST), consensus 4c; Sonic (SONC), consensus 34c; American Campus Communities (ACC), consensus 43c; Cree (CREE), consensus 36c; Fulton Financial (FULT), consensus 20c; Costamare (CMRE), consensus 41c; Hawaiian Holdings (HA), consensus 78c; Ethan Allen (ETH), consensus 36c; Sabra Health (SBRA), consensus 55c; Rush Enterprises (RUSHA), consensus 51c.
October 20, 2014
16:42 EDTMDRMcDermott subsidiary awarded contract by PETRONAS subsidiary
Subscribe for More Information
09:48 EDTMDCOBrdiger Management reports 5.1% passive stake in The Medicines Co.
09:22 EDTCBSTOn The Fly: Pre-market Movers
Subscribe for More Information
07:32 EDTCBSTCubist names Perez CEO to succeed Bonney
Subscribe for More Information
07:30 EDTCBSTCubist names Perez CEO
06:56 EDTCBSTShire reopens acquistion talks with NPS Pharmaceuticals, Cubist, Telegraph says
Subscribe for More Information
October 16, 2014
08:08 EDTAMRNAmarin sees cash and cash equivalents of $135.4M at September 30
Subscribe for More Information
October 15, 2014
10:23 EDTAMRNAmarin management to meet with Oppenheimer
Meeting to be held on the West Coast on October 22 hosted by Oppenheimer.
10:02 EDTDRTXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:54 EDTDRTXDurata Therapeutics downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
October 14, 2014
11:23 EDTCBSTBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
10:01 EDTDRTXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:30 EDTVRNTVerint Systems checks show good deal momentum, says FBR Capital
Subscribe for More Information
07:10 EDTDRTXDurata Therapeutics downgraded to Neutral from Outperform at Credit Suisse
Durata Therapeutics (DRTX ) is being acquired by Actavis (ACT) for $23 per share and $5 in contingent value rights and Credit Suisse does not believe a higher bid will emerge.
October 13, 2014
07:25 EDTMDCOEuropean Association of Cardiothoracic Surgery to hold annual meeting
28th EACTS Annual Meeting is being held in Milan, Italy on October 11-15.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use